**[Supplementary material](https://static-content.springer.com/esm/art%3A10.14283%2Fjpad.2020.69/MediaObjects/42414_2020_69_MOESM1_ESM.docx)**

Table S1. PRISMA-DTA Checklist

Table S2. Detailed electronic Search strategy in PubMed

Table S3. Characteristics of included studies (provided as a separate Excel file)

Table S4. Meta-Regression Analyses Stratified by Multiple Variables for MMSE

Table S5. Meta-Regression Analyses Stratified by Multiple Variables for MoCA

Figure S1. Risk assessment of included studies using QUADAS-2

Figure S2. Meta-regression of MMSE and MoCA to explore the sources of heterogeneity

Figure S3. Deeks’ funnel plot for MMSE and MoCA

**Table S1.PRISMA-DTA Checklist**

|  |  |  |  |
| --- | --- | --- | --- |
| **Section/topic** | **#** | **PRISMA-DTA Checklist Item** | **Reported on page #** |
| **TITLE / ABSTRACT** | | |  |
| Title | 1 | Identify the report as a systematic review (+/- meta-analysis) of diagnostic test accuracy (DTA) studies. | 1 |
| Abstract | 2 | Abstract | 2 |
| **INTRODUCTION** | | |  |
| Rationale | 3 | Describe the rationale for the review in the context of what is already known. | 3-4 |
| Clinical role of index test | D1 | State the scientific and clinical background, including the intended use and clinical role of the index test, and if applicable, the rationale for minimally acceptable test accuracy (or minimum difference in accuracy for comparative design). | 3-5 |
| Objectives | 4 | Provide an explicit statement of question(s) being addressed in terms of participants, index test(s), and target condition(s). | 5 |
| **METHODS** | | |  |
| Protocol and registration | 5 | Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number. | NA |
| Eligibility criteria | 6 | Specify study characteristics (participants, setting, index test(s), reference standard(s), target condition(s), and study design) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. | 5 |
| Information sources | 7 | Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. | 5 |
| Search | 8 | Present full search strategies for all electronic databases and other sources searched, including any limits used, such that they could be repeated. | 5 |
| Study selection | 9 | State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). | 5 |
| Data collection process | 10 | Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. | 5-7 |
| Definitions for data extraction | 11 | Provide definitions used in data extraction and classifications of target condition(s), index test(s), reference standard(s) and other characteristics (e.g. study design, clinical setting). | 6-7 |
| Risk of bias and applicability | 12 | Describe methods used for assessing risk of bias in individual studies and concerns regarding the applicability to the review question. | 7-8 |
| Diagnostic accuracy measures | 13 | State the principal diagnostic accuracy measure(s) reported (e.g. sensitivity, specificity) and state the unit of assessment (e.g. per-patient, per-lesion). | 8-9 |
| Synthesis of results | 14 | Describe methods of handling data, combining results of studies and describing variability between studies. This could include, but is not limited to: a) handling of multiple definitions of target condition. b) handling of multiple thresholds of test positivity, c) handling multiple index test readers, d) handling of indeterminate test results, e) grouping and comparing tests, f) handling of different reference standards | 8-9 |
| Meta-analysis | D2 | Report the statistical methods used for meta-analyses, if performed. | 8-9 |
| Additional analyses | 16 | Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified. | 9 |
| **RESULTS** | | |  |
| Study selection | 17 | Provide numbers of studies screened, assessed for eligibility, included in the review (and included in meta-analysis, if applicable) with reasons for exclusions at each stage, ideally with a flow diagram. | 10 |
| Study characteristics | 18 | For each included study provide citations and present key characteristics including: a) participant characteristics (presentation, prior testing), b) clinical setting, c) study design, d) target condition definition, e) index test, f) reference standard, g) sample size, h) funding sources | 10-11 |
| Risk of bias and applicability | 19 | Present evaluation of risk of bias and concerns regarding applicability for each study. | 11-12 |
| Results of individual studies | 20 | For each analysis in each study (e.g. unique combination of index test, reference standard, and positivity threshold) report 2x2 data (TP, FP, FN, TN) with estimates of diagnostic accuracy and confidence intervals, ideally with a forest or receiver operator characteristic (ROC) plot. | 11-12 |
| Synthesis of results | 21 | Describe test accuracy, including variability; if meta-analysis was done, include results and confidence intervals. | 11-12 |
| Additional analysis | 23 | Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression; analysis of index test: failure rates, proportion of inconclusive results, adverse events). | 12 |
| **DISCUSSION** | | |  |
| Summary of evidence | 24 | Summarize the main findings including the strength of evidence. | 13-16 |
| Limitations | 25 | Discuss limitations from included studies (e.g. risk of bias and concerns regarding applicability) and from the review process (e.g. incomplete retrieval of identified research). | 16-17 |
| Conclusions | 26 | Provide a general interpretation of the results in the context of other evidence. Discuss implications for future research and clinical practice (e.g. the intended use and clinical role of the index test). | 17 |
| **FUNDING** | | |  |
| Funding | 27 | For the systematic review, describe the sources of funding and other support and the role of the funders. | 17-18 |

**Table S2 Detailed electronic search strategy in PubMed (Date Run: 03/31/2022 20:30:40)**

|  |  |  |
| --- | --- | --- |
| Index text | Search strategy in PubMed | Number of studies |
| MMSE | (“Mild Cognitive Impairment” OR MCI) AND (“Alzheimer’s disease” OR AD) AND (“Mini-Mental State Examination” OR MMSE) AND (“Sensitivity and Specificity”) | 1379 |
| MoCA | (“Mild Cognitive Impairment” OR MCI) AND (“Alzheimer’s disease” OR AD) AND (“Montreal Cognitive Assessment”) OR MoCA) AND (“Sensitivity and Specificity”) | 1066 |

**Figure S1.Risk assessment of included studies using QUADAS-2.**

(a) Mini-Mental State Examination [MMSE] (b) Montreal Cognitive Assessment [MoCA]

 



Figure S1.Risk assessment of included studies using QUADAS-2.

(a)MMSE; (b)MoCA; (c) Risk of bias and applicability concerns about each domains

**Table S4. Meta-Regression Analyses Stratified by Multiple Variables for MMSE**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Parameter | category | No. of studies | Sensitivity | p1 | Specificity | p2 | p(Joint Model) |
| Reference | Petersen’s criteria | 35 | 0.70 [0.66 - 0.74] | <0.01 | 0.72 [0.68 - 0.76] | <0.01 | 0.70 |
| standard | other criteria | 18 | 0.73 [0.67 - 0.78] |  | 0.71 [0.65 - 0.76] |  |  |
| Publication | after 2010 | 41 | 0.72 [0.69 - 0.76] | 0.03 | 0.70 [0.66 - 0.73] | <0.01 | 0.05 |
| year | before2010 | 12 | 0.64 [0.56 - 0.71] |  | 0.77 [0.71 - 0.83] |  |  |
| Country | from Asia | 28 | 0.74 [0.70 - 0.78] | <0.01 | 0.68 [0.64 - 0.72] | <0.01 | 0.03 |
| location | other continents | 25 | 0.67 [0.62 - 0.72] |  | 0.75 [0.71 - 0.79] |  |  |
| No. of | >200 | 22 | 0.70 [0.65 - 0.75] | <0.01 | 0.73 [0.69 - 0.77] | <0.01 | 0.59 |
| patients | ≤200 | 31 | 0.71 [0.67 - 0.76] |  | 0.70 [0.65 - 0.74] |  |  |

**Table S5. Meta-Regression Analyses Stratified by Multiple Variables for MoCA**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Parameter | category | No. of studies | Sensitivity | p1 | Specificity | p2 | p(Joint Model) |
| Reference | Petersen’s criteria | 37 | 0.85 [0.82 - 0.88] | <0.01 | 0.80 [0.76 - 0.83] | <0.01 | 0.82 |
| standard | other criteria | 26 | 0.86 [0.82 - 0.89] |  | 0.78 [0.74 - 0.82] |  |  |
| Publication | after 2010 | 56 | 0.85 [0.82 - 0.87] | <0.01 | 0.78 [0.75 - 0.81] | <0.01 | 0.03 |
| year | before2010 | 7 | 0.91 [0.85 - 0.96] |  | 0.85 [0.80 - 0.91] |  |  |
| Country | from Asia | 36 | 0.86 [0.83 - 0.89] | <0.01 | 0.79 [0.76 - 0.83] | <0.01 | 0.76 |
| location | other continents | 27 | 0.84 [0.81 - 0.88] |  | 0.79 [0.75 - 0.83] |  |  |
| No. of | >200 | 20 | 0.85 [0.81 - 0.89] | <0.01 | 0.78 [0.74 - 0.82] | <0.01 | 0.87 |
| patients | ≤200 | 43 | 0.86 [0.83 - 0.89] |  | 0.80 [0.76 - 0.83] |  |  |

**Figure S2：**



Figure S2. Meta-regression of MMSE and MoCA to explore the sources of heterogeneity

**Figure S3:**



Figure S3. Deeks’ funnel plot for MMSE and MoCA, a p value of 0.20 and 0.96 indicates absence of publication bias. ESS = effective sample size